Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionated WPRT in Prostate Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

58 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-07

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to determine if 5 (five) fractions of external radiotherapy with higher radiation doses per fraction to the pelvis leads to similar results to the standard of care external radiotherapy treatment that is comprised of 25 fractions of external radiotherapy with lower radiation doses per fraction to the pelvis.

This study aims to investigate the impact in quality of life associated with hypofractionated Whole Pelvis Radiotherapy (WPRT) in comparison to conventionally-fractionated WPRT in patients with unfavorable-intermediate and high-risk prostate cancers. This information is valuable as hypofractionated WPRT is a more attractive and convenient treatment approach, and may become the new standard of care if proven to be well-tolerated and effective. Therefore, this study aims to provide a more rational justification for use of hypofractionated WPRT in future larger randomized trials by comparing this strategy with the current standard of care. This study will also provide an initial understanding of the toxicity profile and cancer control associated with hypofractionated WPRT and High Dose Rate Brachytherapy (HDR-BT).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer

NCT05361902

Prostate Cancer

ACTIVE_NOT_RECRUITING NA

Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer

NCT01921803

Prostate Cancer

COMPLETED PHASE2

SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer

NCT04861415

Prostate Cancer

RECRUITING NA

Hypofractionated WPPT With HDR Boost

NCT06591819

Prostate Cancer

RECRUITING PHASE2

Standard Moderately Hypofractionated RT vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer

NCT05705921

Prostate Cancer

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventionally-fractionated WPRT

15 Gy HDR brachytherapy boost will be administered followed by 45 Gy WPRT in 25 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.

Group Type ACTIVE_COMPARATOR

Conventionally-fractionated WPRT

Intervention Type RADIATION

Total dose: 45 Gy in 25 fractions WPRT

Hypofractionated WPRT

15 Gy HDR brachytherapy boost will be administered followed by 25 Gy WPRT in 5 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.

Group Type EXPERIMENTAL

Hypofractionated WPRT

Intervention Type RADIATION

Total dose: 25 Gy in 5 fractions WPRT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Conventionally-fractionated WPRT

Total dose: 45 Gy in 25 fractions WPRT

Intervention Type RADIATION

Hypofractionated WPRT

Total dose: 25 Gy in 5 fractions WPRT

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 or older
* Study Informed Consent provided
* Pathologically proven diagnosis of prostatic adenocarcinoma
* Unfavorable intermediate risk \[with greater than 15% chance of node involvement based on Memorial Sloan Kettering Cancer Center (MSKCC) nomogram https://www.mskcc.org/nomograms/prostate\] or high or very-high-risk prostate cancer based on National Comprehensive Cancer Network (NCCN) classification \[Prostatic Specific Antigen (PSA) \> 20 ng/mL or clinical cT3a or cT3b or Gleason 8-10\]
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
* No prior history of pelvic irradiation, brachytherapy, cryosurgery, High-Intensity Focused Ultrasound (HIFU), Transurethral Resection of the Prostate (TURP) or radical prostatectomy

Exclusion Criteria

* Presence of nodal or distant metastasis, as confirmed by Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) of the chest/abdomen/pelvis and bone scan within 45 days of randomization
* Plan for adjuvant docetaxel post-radiotherapy
* Serious medical comorbidities or other contraindications to HDR-BT
* Presence of inflammatory bowel disease
* Presence of connective tissue disease
* Medically unfit for general anesthesia
* Unable or unwilling to complete questionnaires

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No